Efficacy and Safety of a Natural Supplement Containing Serenoa Repens, Solanum Lycopersicum, Lycopene, and Bromelain in Reducing Symptoms of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Cohort Study in 250 Patients
Authors:
- Luca LambertiniLLLuca Lambertini
- Alessandro SandulliASAlessandro Sandulli
- Vincenzo SalamoneVSVincenzo Salamone
- Mara BacchianiMBMara Bacchiani
- Sofia GiudiciSGSofia Giudici
- Eleana MassaroEMEleana Massaro
- Anna CadenarACAnna Cadenar
- Riccardo MariottiniRMRiccardo Mariottini
- Simone CocoSCSimone Coco
- Laia BardinaLBLaia Bardina
- Elena CiaralliECElena Ciaralli
- Marco SaladinoMSMarco Saladino
Open Access
Abstract
Background: Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III is a widespread condition affecting men universally, with existing treatments showing limited success. This study evaluated the efficacy and safety of a natural supplement, composed of Serenoa repens, Solanum lycopersicum, lycopene, and bromelain, in managing symptoms of this condition among a substantial patient group. Methods: In this prospective study, 245 patients diagnosed with Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III were treated with the aforementioned supplement, alongside lifestyle alterations, such as refraining from spicy foods, alcohol, caffeine, and cycling, for a duration of three months. Patients’ progress was assessed at one and three months using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Index (IPSS), quality of life (QoL) scores, and changes in total prostate-specific antigen (PSA) levels. Results: The supplement was well received with no serious adverse events reported. Significant improvements were observed in NIH-CPSI scores, IPSS, QoL scores, and a substantial decrease in total PSA levels at three months compared to baseline, with a positive trend noted from one-month to three-month evaluations. This was consistent in either patients with predominantly voiding or storage urinary symptoms. Conclusions: Our results suggest that this natural supplement in conjunction with lifestyle changes could offer a safe and effective alternative treatment for patients suffering from Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III. However, these findings require validation through further large-scale randomized controlled trials.Keywords
This publication has 24 references indexed in Scilit:
- Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS TrialJournal of Urology, 2016
- Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain SyndromeEuropean Urology, 2016
- Anti‐inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasiaThe Prostate, 2015
- Prostate cancer and inflammation: the evidenceHistopathology, 2011
- Long-Term Efficacy of Serenoa repens Treatment in Patients with Mild and Moderate Symptomatic Benign Prostatic HyperplasiaUrologia Internationalis, 2011
- Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromesProstate Cancer and Prostatic Diseases, 2008
- THE NATIONAL INSTITUTES OF HEALTH CHRONIC PROSTATITIS SYMPTOM INDEX: DEVELOPMENT AND VALIDATION OF A NEW OUTCOME MEASUREJournal of Urology, 1999
- NIH Consensus Definition and Classification of ProstatitisJAMA, 1999
- Saw Palmetto Extracts for Treatment of Benign Prostatic HyperplasiaJAMA, 1998
- Inhibition of androgen metabolism and binding by a liposterolic extract of “serenoa repens B” in human foreskin fibroblastsJournal of Steroid Biochemistry, 1984